


Q&A with Michael Kormann, Group Leader, Pediatric Infectiology and Immunology, Eberhard-Karls-University Tuebingen

RNA Therapeutics 2015, 16th & 17th February, Marriott Regents Park Hotel, London UK.

LONDON, LONDON, UNITED KINGDOM, November 21, 2014 /EINPresswire.com/ -- In the run up to SMI's 6th annual event on [RNA Therapeutics](#), Professor Dr Michael Kormann from Eberhard-Karls-University, was asked a few questions about the conference taking place on 16th and 17th February 2015 in London and about RNA Therapeutics. Dr Michael Kormann will be providing unique insights on Biochemically modified messenger RNA encoding nucleases for in vivo gene correction of severe inherited lung diseases. The talk will discuss modified messenger RNA, in vivo treatment, life-saving efficacy and limiting off-target effects.



Dr Michael Kormann

Q. About you – what is your role and what perspective do you bring to the conference?

“

mRNA has the pivotal advantage to be non-genotoxic and will revolutionize all nuclease based gene manipulating systems (ZFNs, TALENs, CRISPR systems).”

Dr Michael Kormann

I'm a key inventor of mRNA therapeutics in mouse models (mRNA therapy for SP-B deficiency and asthma; mRNA to encode site-specific nucleases for in vivo gene correction!

Q. What will attendees take away from your talk?

They will understand that mRNA has the pivotal advantage to be non-genotoxic and will revolutionize all nuclease based gene manipulating systems (ZFNs, TALENs, CRISPR systems).

Q. Are there any sessions you are particularly looking forward to and why?

I'm looking fwd. to the talks of:

- Rodger Novak: extremely interesting how the CRISPR system world develops and developed!
- Jesper Wengel: the use of aptamers to TARGET specific cells will become very important!

Q. What lessons can be learnt following several decades of RNA Therapeutics?

RNA therapeutics are getting more and more important, as mRNA is completely controllable by modifications, and therefore a reliable tool for oncology (CARs, T cell and DC loading), gene addition and gene supplementation.

Q. What do you believe are the biggest challenges in the industry?

Bringing the technology of RNA therapeutics to the clinics. In every aspect. Especially for in vivo gene and genome correction. However, I think it will revolutionize this part of gene therapy, as mRNA encoded nucleases are much safer with much less off-target cutting than any other technology at the moment.

The 6th annual conference on RNA Therapeutics takes place on 16-17 February 2015 at the Marriott Regents Park Hotel in London UK. Further details are available online at www.therapeutics-rna.com

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/235902311>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.